Anzeige
Mehr »
Dienstag, 13.05.2025 - Börsentäglich über 12.000 News
Wenn Rendite auf Sicherheit trifft: Warum Almonty Industries plötzlich jeder will!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H63F | ISIN: US84833T1034 | Ticker-Symbol: 2HA
Tradegate
12.05.25 | 13:57
0,566 Euro
+2,72 % +0,015
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SPERO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPERO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5420,56215:53
0,5420,56215:53

Aktuelle News zur SPERO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAn Overview of Spero Therapeutics' Earnings3
28.04.Spero Therapeutics ernennt neue CEO und Vorstandskandidatin6
28.04.Spero Therapeutics appoints new CEO and board nominee1
28.04.Spero Therapeutics appoints Esther Rajavelu as president, CEO2
28.04.Spero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer173CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for...
► Artikel lesen
28.04.Spero Therapeutics, Inc. - 8-K, Current Report1
SPERO THERAPEUTICS Aktie jetzt für 0€ handeln
08.04.The Spero Clinic: When a Simple Ankle Injury Turns Into CRPS: Moana Ruhfass's Journey266FAYETTEVILLE, ARKANSAS / ACCESS Newswire / April 8, 2025 / While, for most children, life is an adventure and a never-ending road of discovery, many others are not that lucky, facing a journey of pain...
► Artikel lesen
28.03.Spero halts development on another antibiotic in latest reprioritization9
27.03.Spero Therapeutics, Inc. - 8-K, Current Report2
27.03.Spero Therapeutics GAAP EPS of -$0.38 misses by $0.07, revenue of $15.04M13
27.03.Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update213Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis...
► Artikel lesen
26.03.A Glimpse of Spero Therapeutics' Earnings Potential8
20.03.Redefining Recovery: Real Patient Perspectives on Holistic Healing at the Spero Clinic With Tara Rae Moss319 FAYETTEVILLE, ARKANSAS / ACCESS Newswire / March 20, 2025 / Imagine being a bestselling author, speaker and advocate, living life 1000 miles per hour and then, suddenly and seemingly without a cause...
► Artikel lesen
28.02.Spero Therapeutics, Inc. - 8-K, Current Report7
04.02.From Wheelchair to Hope: Marjorie's Journey to Walking Again With the Spero Clinic597Long COVID patient finds hope, and help through The Spero Clinic's neurological relief program. FAYETTEVILLE, ARKANSAS / ACCESS Newswire / February 3, 2025 / In a world plagued by chronic and invisible...
► Artikel lesen
30.01.The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts31
10.01.Spero Therapeutics kündigt vorübergehende Führungsänderungen16
10.01.Spero Therapeutics announces interim leadership amid SEC inquiry4
10.01.Spero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes324Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice...
► Artikel lesen
10.01.Spero Therapeutics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,20